![](https://investorshub.advfn.com/uicon/477123.png?cb=1533675489)
Friday, March 24, 2017 1:10:10 PM
Angelo- If you look at the latest presentation on page 30 they say:
Any additional revenue that would appear on IPCI's 1st Qtr filing would have to be from a Milestone payment... of which we're still not sure of... but they are certainly not getting any royalty money... YET.
2. Additional revenues from Endo (PAR) launch of generic Focalin®XR 5, 10, 20, 40mg strengths
That won't happen as they have not yet launched those doses... unless they have launched and not PR'ed it.
p.s. the way I read it.... we are entitled to a milestone payment on the launch of the 25mg and 35mg as they have paragraph 4 exclusivity... I don't believe it applied only to the 15mg and 30mg... just my interpretation of the agreement.
Recent IPCI News
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - IPCI • PR Newswire (Canada) • 03/06/2024 12:55:00 PM
- Canadian Investment Regulatory Organization Trading Halt - IPCI • PR Newswire (Canada) • 03/06/2024 12:51:00 PM
FEATURED ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM